PNC Financial Services Group Inc. Reduces Stake in Supernus Pharmaceuticals Inc (SUPN)

PNC Financial Services Group Inc. trimmed its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 205,855 shares of the specialty pharmaceutical company’s stock after selling 2,682 shares during the period. PNC Financial Services Group Inc. owned 0.39% of Supernus Pharmaceuticals worth $10,365,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Supernus Pharmaceuticals by 8.7% in the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock valued at $460,287,000 after purchasing an additional 618,722 shares during the period. Wells Fargo & Company MN increased its holdings in Supernus Pharmaceuticals by 6.8% in the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after purchasing an additional 61,100 shares during the period. FMR LLC increased its holdings in Supernus Pharmaceuticals by 1,909.6% in the second quarter. FMR LLC now owns 941,300 shares of the specialty pharmaceutical company’s stock valued at $56,337,000 after purchasing an additional 894,459 shares during the period. Renaissance Technologies LLC increased its holdings in Supernus Pharmaceuticals by 191.3% in the second quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after purchasing an additional 580,990 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Supernus Pharmaceuticals by 21.6% in the second quarter. Janus Henderson Group PLC now owns 665,392 shares of the specialty pharmaceutical company’s stock valued at $39,824,000 after purchasing an additional 118,289 shares during the period. Institutional investors own 97.83% of the company’s stock.

Shares of Supernus Pharmaceuticals stock opened at $44.75 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65. Supernus Pharmaceuticals Inc has a 1-year low of $34.90 and a 1-year high of $61.25. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 35.52, a price-to-earnings-growth ratio of 1.42 and a beta of 0.92.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The firm had revenue of $102.99 million during the quarter, compared to the consensus estimate of $100.75 million. During the same period last year, the business posted $0.29 EPS. The business’s revenue was up 28.1% compared to the same quarter last year. On average, sell-side analysts forecast that Supernus Pharmaceuticals Inc will post 1.87 earnings per share for the current year.

A number of analysts recently weighed in on SUPN shares. Cantor Fitzgerald restated a “buy” rating and issued a $56.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. Mizuho started coverage on Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective for the company. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 30th. B. Riley decreased their price objective on Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating for the company in a report on Monday, November 12th. Finally, Piper Jaffray Companies set a $44.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, August 28th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $56.00.

ILLEGAL ACTIVITY NOTICE: “PNC Financial Services Group Inc. Reduces Stake in Supernus Pharmaceuticals Inc (SUPN)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/11/30/pnc-financial-services-group-inc-reduces-stake-in-supernus-pharmaceuticals-inc-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Recommended Story: What is Cost of Capital?

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply